Matthew Roden (MPM Capital)

Af­ter lead­ing Cel­gene buy­out, Matthew Ro­den leaves Bris­tol My­ers Squibb for ven­ture cap­i­tal firm

The past four years at Bris­tol My­ers Squibb have been busy for Matthew Ro­den. The se­nior VP and head of en­ter­prise strat­e­gy was be­hind the com­pa­ny’s ini­tial plan fol­low­ing its ma­jor $74 bil­lion Cel­gene buy­out last year. But now, it’s on to green­er pas­tures.

Ro­den’s been tapped as ex­ec­u­tive part­ner at Cam­bridge, MA-based ven­ture cap­i­tal firm MPM Cap­i­tal —  a move he said has al­ways been part of his long-term goals.

“Go­ing in­to ven­ture cap­i­tal was part of my long-term plan … and it did hap­pen a lit­tle bit faster than I ex­pect­ed. But cer­tain op­por­tu­ni­ties have opened up over the past year. And … MPM specif­i­cal­ly, I’ve al­ways had a huge re­spect for their track record and for the peo­ple there,” Ro­den told End­points News.

Ro­den, a self-de­scribed “sci­ence nerd,” said he knew ear­ly on in grad­u­ate school that he want­ed to mar­ry his in­ter­ests in cap­i­tal mar­kets, sci­ence and tech­nol­o­gy. In 2005, he joined Cred­it Su­isse as an as­so­ciate an­a­lyst, where he worked for a year be­fore be­com­ing vice pres­i­dent at JP Mor­gan. Then in 2010, he jumped to the Swiss in­vest­ment bank­ing firm UBS as biotech eq­ui­ty re­search sec­tor head.

On the BMS R&D lead­er­ship team rep­re­sent­ing ex­ter­nal in­no­va­tion, Ro­den led teams on more than 100 busi­ness de­vel­op­ment trans­ac­tions, in­clud­ing the Cel­gene ac­qui­si­tion, which gave the com­pa­ny late-stage can­di­dates like im­munol­o­gy and in­flam­ma­tion drugs TYK2 and ozan­i­mod.

“You know I ac­com­plished a lot in a rel­a­tive­ly short pe­ri­od of time at BMS, which made it pos­si­ble to … ac­cel­er­ate my long-term plan of mov­ing to ven­ture,” he said.

At MPM, Ro­den will be re­spon­si­ble for iden­ti­fy­ing and as­sess­ing new tech­nolo­gies and ad­vis­ing port­fo­lio ex­ec­u­tives on busi­ness and clin­i­cal strate­gies.

“I want to be part of build­ing great biotech com­pa­nies — the next wave in­no­va­tors,” he said.

“Matt’s ex­pe­ri­ence and suc­cess as a bio­phar­ma­ceu­ti­cal ex­ec­u­tive, a biotech eq­ui­ty re­search an­a­lyst, and a sci­en­tist bring a tri­fec­ta of unique and valu­able in­sight to our in­vest­ment team and the MPM port­fo­lio,” Ans­bert Gadicke, MPM co-founder and man­ag­ing di­rec­tor, said in a state­ment.

Janet Woodcock (Greg Nash/Pool via AP Images)

'I re­al­ly don’t look back': Janet Wood­cock on her tran­si­tion away from drugs

Janet Woodcock may have one of the most historically long and drug-intense tenures in FDA history, but her new role is outside of all things pharma and the once-acting FDA commissioner isn’t looking back.

“No I really don’t look back,” Woodcock told Endpoints News via email on Monday morning. “Yes I will be transitioning. Longer discussion on infrastructure needed.”

Co­pay coupons gone wrong, again: Pfiz­er pays al­most $300K to set­tle com­plaints in four states

Pfizer has agreed to pay $290,000 to settle allegations of questionable copay coupon practices in Arizona, Colorado, Kansas, and Vermont from 2014 to 2018.

While the company has not admitted any wrongdoing as part of the settlement, Pfizer has agreed to issue restitution checks to about 5,000 consumers.

A Pfizer spokesperson said the company has “enhanced its co-pay coupons to alleviate the concerns raised by states and agreed to a $30,000 payment to each.”

Delaware court rules against Gilead and Astel­las in years-long patent case

A judge in Delaware has ruled against Astellas Pharma and Gilead in a long-running patent case over Pfizer-onwed Hospira’s generic version of Lexiscan.

The case kicked off in 2018, after Hospira submitted an Abbreviated New Drug Application (ANDA) for approval to market a generic version of Gilead’s Lexiscan. The drug is used in myocardial perfusion imaging (MPI), a type of nuclear stress test.

Taye Diggs (courtesy Idorsia)

Idor­sia inks an­oth­er celebri­ty en­dors­er deal with ac­tor and dad Taye Dig­gs as Qu­viviq in­som­nia am­bas­sador

Idorsia’s latest Quviviq insomnia campaign details the relatable dad story of a well-known celebrity — actor and Broadway star Taye Diggs.

Diggs stopped sleeping well after the birth of his son, now more than 10 years ago. Switching mom-and-dad nightly shifts to take care of a baby interrupted his sleep patterns and led to insomnia.

“When you’re lucky enough to be living out your dream and doing what you want, but because of something as simple as a lack of sleep, you’re unable to do that, it felt absolutely — it was treacherous,” he says in an interview-style video on the Quviviq website.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,600+ biopharma pros reading Endpoints daily — and it's free.

Belén Garijo, Merck KGaA CEO (Kevin Wolf/AP Images for EMD Serono)

Mer­ck KGaA pumps €440M in­to ex­pand­ing and con­struct­ing Irish man­u­fac­tur­ing fa­cil­i­ties

The area of Ireland famous for Blarney Castle and its cliffsides along the Atlantic Ocean is seeing Merck KGaA expand its commitment there.

The German drug manufacturer is expanding its membrane and filtration manufacturing capabilities in Ireland. The company will invest approximately €440 million ($470 million) to increase membrane manufacturing capacity in Carrigtwohill, Ireland, and build a new manufacturing facility at Blarney Business Park, in County Cork, Ireland.

Rep. Katie Porter (D-CA) (Michael Brochstein/Sipa USA/Sipa via AP Images)

House Dems to Sen­ate lead­er­ship: Quick­ly move a rec­on­cil­i­a­tion bill with drug price ne­go­ti­a­tion re­forms

Twenty House Democrats, including Reps. Katie Porter of California and Susan Wild of Pennsylvania, are calling on Senate leaders to move quickly with a reconciliation bill (meaning they only need a simple majority for passage) with prescription drug pricing reforms, and to include adding new authority for Medicare to negotiate drug prices.

They also called on the Senate to specifically follow suit with the House passage of a $35 per month insulin cap (as Senate Majority Leader Chuck Schumer’s deadline for a vote on that provision has come and gone), and to cap Medicare Part D costs at $2,000 per year for seniors.

An NYU surgeon transplants an engineered pig kidney into the outside of a brain-dead patient (Joe Carrotta/NYU Langone Health)

'Xeno­trans­plan­ta­tion is com­ing': New NE­JM pa­per gives de­tailed look in­to 2 pig-to-hu­man kid­ney trans­plant cas­es

The thymokidney is a curious organ, if you could call it that. It’s a sort of Frankensteinian creation — a system of pig thymus embedded underneath the outer layer of a pig’s kidney, made for human transplantation.

In the first case of pig-to-human xenotransplantation of a kidney into a brain-dead patient, the thymokidney quietly featured front and center.

In that experiment, which took place in September of last year, NYU researchers led by Robert Montgomery sutured a pig thymokidney onto the leg of a brain-dead 66-year-old woman. That case was widely reported on by a horde of major media outlets, including the New York Times, the BBC, and an in-depth feature by USA Today.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,600+ biopharma pros reading Endpoints daily — and it's free.

Phillip Gomez, SIGA CEO

UP­DAT­ED: On the back of SIGA Tech­nolo­gies' win with the FDA, the mon­key­pox virus sees the com­pa­ny spring­ing to fur­ther ac­tion

As the cases of monkeypox now sit at well over 100 worldwide and have spread to multiple continents, the orders for any type of vaccine against monkeypox are seeing nations and medical bodies looking to get their hands on anything and everything. And now SIGA Technologies seems to be getting in on the action.

According to Euronews, SIGA Technologies, a pharmaceutical company that is focused on providing medical countermeasures to biological and chemical attacks, is now in talks with several European authorities looking to stockpile its antiviral that can counter monkeypox. The drug known as tecovirimat or Tpoxx was approved by the FDA in 2018 as a vaccine for smallpox but was approved by the European Medicines Agency to also act against monkeypox, cowpox and complications from immunization with vaccinia.

Vlad Coric, Biohaven CEO

UP­DAT­ED: Fresh off $11.6B sale to Pfiz­er, New Bio­haven hits Phase III set­back just weeks af­ter Vlad Coric chalked up promise

When Pfizer bought up Biohaven’s migraine portfolio in the largest M&A deal of the year earlier this month, Biohaven CEO Vlad Coric promised the rest of the pipeline, which will live on under the umbrella of New Biohaven, still has a lot to offer. But that vision took a dent Monday as the drugmaker revealed it’s once again flopped on troriluzole.

The glutamate regulator failed to meet the primary endpoint on a Phase III study in patients with spinocerebellar ataxia, an inherited disorder that impairs a person’s ability to walk, speak and swallow. SCA can also lead to premature death.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,600+ biopharma pros reading Endpoints daily — and it's free.